Physician profile
Steven J Becker
NPI 1447348628
$10,712.81
in general payments reported to CMS, 2019-2025
40 companies · $799 in 2025
The $799 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,802 · 2020: $870 · 2021: $1,418 · 2022: $1,772 · 2023: $1,340 · 2024: $1,711 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,850.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,427.91 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $1,879.60 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk As | $1,310.09 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $753.29 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $726.46 | 2022-2025 | |
| Novo Nordisk INC | $383.38 | 2019-2025 | Wegovy, Ozempic |
| Dexcom, INC. | $339.67 | 2022-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $308.00 | 2019-2025 | Evenity, Prolia, Repatha |
| Janssen Biotech, INC. | $284.02 | 2022-2024 | Tremfya |
| Novartis Pharmaceuticals Corporation | $229.33 | 2019-2023 | |
| Glaxosmithkline, LLC. | $226.91 | 2019-2025 | Arexvy |
| Tandem Diabetes Care, INC. | $197.37 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Coloplast Corp | $158.08 | 2019 | |
| Eisai INC. | $144.78 | 2021 | |
| Amarin Pharma, INC. | $135.65 | 2019-2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.